(4-(5-amino-6-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-yl)phenyl)(morpholino)methanone | 1450666-71-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: (4-(5-amino-6-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-yl)phenyl)(morpholino)methanone
• 英文别名: 5-{4-[(morpholin-4-yl)carbonyl]phenyl}-3-[6-(trifluoromethyl)pyridin-3-yl]pyrazin-2-amine；[4-[5-Amino-6-[6-(trifluoromethyl)-3-pyridyl]pyrazin-2-yl]phenyl]-morpholino-methanone；[4-[5-amino-6-[6-(trifluoromethyl)pyridin-3-yl]pyrazin-2-yl]phenyl]-morpholin-4-ylmethanone
• CAS: 1450666-71-3
• 化学式: C₂₁H₁₈F₃N₅O₂
• 分子量: 429.401
• InChiKey: OIZOYBBNHJPCGH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  31
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  94.2
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  4-(吗啉-4-羰基)苯基硼酸 、 5-bromo-3-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-amine 在 bis-triphenylphosphine-palladium(II) chloride 、 potassium carbonate 作用下， 以 1,4-二氧六环 为溶剂， 反应 16.0h， 以55%的产率得到(4-(5-amino-6-(6-(trifluoromethyl)pyridin-3-yl)pyrazin-2-yl)phenyl)(morpholino)methanone
  参考文献：
  名称：

  Structure–Activity-Relationship Studies around the 2-Amino Group and Pyridine Core of Antimalarial 3,5-Diarylaminopyridines Lead to a Novel Series of Pyrazine Analogues with Oral in Vivo Activity

  摘要：

  Replacement of the pyridine core of antimalarial 3,5-diaryl-2-aminopyridines led to the identification of a novel series of pyrazine analogues with potent oral antimalarial activity. However, other changes to the pyridine core and replacement or substitution of the 2-amino group led to loss of antimalarial activity. The 3,5-diaryl-2-arninopyrazine series showed impressive in vitro antiplasmodial activity against the K1 (multidrug resistant) and NF54 (sensitive) strains of Plasmodium falciparum in the nanomolar IC50 range of 6-94 nM while also demonstrating good in vitro metabolic stability in human liver microsomes. In the Plasmodium berghei mouse model, this series generally exhibited good efficacy at low oral doses. One of the frontrunner compounds, 4, displayed potent in vitro antiplasmodial activity with IC50 values of 8.4 and 10 nM against the K1 and NF54 strains, respectively. When evaluated in P. berghei-infected mice, compound 4 was completely curative at an oral dose of 4 x 10 mg/kg.

  DOI：

  10.1021/jm401278d

文献信息

• [EN] ANTI -MALARIAL AGENTS<br/>[FR] AGENTS ANTI-PALUDIQUES
  申请人：UNIV CAPE TOWN

  公开号：WO2013121387A1

  公开（公告）日：2013-08-22

  The present invention is related to a use of aminopyrazine derivatives in the manufacture of a medicament for preventing or treating malaria. Specifically, the present invention is related to aminopyrazine derivatives useful for the preparation of a pharmaceutical formulation for the inhibition of malaria parasite proliferation.

  本发明涉及使用氨基吡嗪衍生物制造预防或治疗疟疾的药物。具体而言，本发明涉及用于制备药物制剂以抑制疟原虫增殖的氨基吡嗪衍生物。
• ANTI-MALARIAL AGENTS
  申请人：University Of Cape Town

  公开号：EP2814820B1

  公开（公告）日：2016-07-20
• US9266842B2
  申请人：——

  公开号：US9266842B2

  公开（公告）日：2016-02-23
• Structure–Activity-Relationship Studies around the 2-Amino Group and Pyridine Core of Antimalarial 3,5-Diarylaminopyridines Lead to a Novel Series of Pyrazine Analogues with Oral in Vivo Activity
  作者：Yassir Younis、Frederic Douelle、Diego González Cabrera、Claire Le Manach、Aloysius T. Nchinda、Tanya Paquet、Leslie J. Street、Karen L. White、K. Mohammed Zabiulla、Jayan T. Joseph、Sridevi Bashyam、David Waterson、Michael J. Witty、Sergio Wittlin、Susan A. Charman、Kelly Chibale

  DOI：10.1021/jm401278d

  日期：2013.11.14

  Replacement of the pyridine core of antimalarial 3,5-diaryl-2-aminopyridines led to the identification of a novel series of pyrazine analogues with potent oral antimalarial activity. However, other changes to the pyridine core and replacement or substitution of the 2-amino group led to loss of antimalarial activity. The 3,5-diaryl-2-arninopyrazine series showed impressive in vitro antiplasmodial activity against the K1 (multidrug resistant) and NF54 (sensitive) strains of Plasmodium falciparum in the nanomolar IC50 range of 6-94 nM while also demonstrating good in vitro metabolic stability in human liver microsomes. In the Plasmodium berghei mouse model, this series generally exhibited good efficacy at low oral doses. One of the frontrunner compounds, 4, displayed potent in vitro antiplasmodial activity with IC50 values of 8.4 and 10 nM against the K1 and NF54 strains, respectively. When evaluated in P. berghei-infected mice, compound 4 was completely curative at an oral dose of 4 x 10 mg/kg.